Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2003
12/04/2003US20030224045 Combination immediate release sustained release levodopa/carbidopa dosage forms
12/04/2003US20030224043 Increasing the bioavailability of low solubility drugs, including a disintegrant and a porosigen promoting disintegrate in less than 10 minutes; high speed, drug delivery
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223990 A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. 193P1E1 provides
12/04/2003US20030223982 Enzymes in topical cosmetic or pharmaceutical compositions for the prevention of the ageing of human skin. In particular, the method prevents ageing effects caused by light. The method prevents the degradation of collagen within connective tissue
12/04/2003US20030223972 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
12/04/2003US20030223936 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2489145A1 Insulin-sensitizing agent
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487153A1 New formulation for the parenteral application of crobenetine
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2487021A1 Probiotics and oral tolerance
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486966A1 Substituted quinazolinone compounds
12/04/2003CA2486962A1 Compounds
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486704A1 Anti-cancer formulation
12/04/2003CA2486651A1 Sulfone liver x-receptor modulators
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485984A1 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003CA2485972A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003CA2485825A1 Method for identification of a ligand whereby receptor residence time is measured
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2480756A1 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
12/04/2003CA2480742A1 Tropane compounds
12/03/2003EP1367060A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
12/03/2003EP1367058A1 Tetrahydropyran derivatives
12/03/2003EP1367054A1 Heterocyclic factor Xa inhibitors
12/03/2003EP1367051A2 Inhibitors of tumor necrosis factor alpha
12/03/2003EP1366773A1 Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
12/03/2003EP1366772A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
12/03/2003EP1366771A2 Use of the neurotoxic compnent of botulinum toxins as a medicament
12/03/2003EP1366770A2 Use of botulinum toxin for treating muscle-associated pain
12/03/2003EP1366760A1 Tablets quickly disintegrated in oral cavity
12/03/2003EP1366175A2 Multifunctional protease inhibitors and their use in treatment of disease
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366157A2 Compositions and methods for the therapy and diagnosis of lung cancer
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366074A2 Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
12/03/2003EP1366065A1 Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs
12/03/2003EP1366064A1 Tumour targeting prodrugs activated by metallo matrixproteinases
12/03/2003EP1366055A2 Antiviral agents for treatment of flaviviridae infections
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366044A1 8-[4-[3-(5-fluoro-1h-indol-3-yl)propyl]-1-piperazinyl]-2-methyl-2h-1, 4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the serotonin reuptake site
12/03/2003EP1366039A1 Piperazinylcarbonylquinolines and -isoquinolines
12/03/2003EP1366038A1 Cdk-1 inhibitor oxindoles and the application thereof in therapeutics
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366033A1 Chemical compounds
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366022A1 Rgd-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects
12/03/2003EP1366021A2 Substituted diarylureas as stimulators for fas-mediated apoptosis
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1366012A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
12/03/2003EP1366007A2 Compounds with high monoamine transporter affinity
12/03/2003EP1365812A2 Pharmaceutical composition having reduced tendency for drug crystallization
12/03/2003EP1365808A2 Compositions for antitumour treatment containing ecteinascidin 743
12/03/2003EP1365804A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
12/03/2003EP1365781A1 Acrochordon alleviation
12/03/2003EP1365771A1 Method of treating certain eye diseases
12/03/2003EP1365769A1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
12/03/2003EP1365766A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid
12/03/2003EP1365765A2 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
12/03/2003EP1365763A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
12/03/2003EP1365762A1 Method for increasing leptin levels using nicotinic acid compounds
12/03/2003EP1365761A1 Therapeutic combination of amlodipine and benazepril
12/03/2003EP1365760A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/03/2003EP1365759A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
12/03/2003EP1365753A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
12/03/2003EP1365748A2 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
12/03/2003EP1365726A2 Method for evaluating therapeutic efficacy
12/03/2003EP1365651A1 Composition and methods for modulation of vascular structure and/or function
12/03/2003EP1365645A2 Transgenic mice containing targeted gene disruptions
12/03/2003EP1283838B1 Piperazine and piperidine compounds
12/03/2003EP1257555B1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/03/2003EP1165184B1 Estrogen receptor-beta antagonism and bone diseases
12/03/2003EP1150963B1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
12/03/2003EP1027351B1 Phenanthroline derivatives
12/03/2003EP0854715B1 Methods of inhibiting plasminogen activator inhibitor 1
12/03/2003EP0821004B1 Peptides and remedy for bone diseases containing the same as active ingredient
12/03/2003EP0767666B1 Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
12/03/2003CN1460181A Nucleic acid sequences and protein involved in cellular senescence
12/03/2003CN1460109A Improved specificity in treatment of diseases
12/03/2003CN1460105A 黄嘌呤磷酸二酯酶v抑制剂 Xanthine phosphodiesterase inhibitor v
12/03/2003CN1460025A Immunomodulatory human MHC class Ôàí antigen-binding polypeptides
12/03/2003CN1460024A Use of FVIIa or tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
12/03/2003CN1459312A Traditional Chinese medicine for treating deformed soft-tissue
12/03/2003CN1459300A Prepn. for sobering use
12/03/2003CN1459297A Oral liquor with functions of relieving summer heat, antithermic and refreshment
1 ... 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 ... 1564